Cash from Financing (Quarterly) Chart

View Cash from Financing (Quarterly) for GDRX.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Financing (Quarterly) Chart
Start Trial

Historical Cash from Financing (Quarterly) Data

View and export this data back to 2020. Start Trial.
Date Value
June 30, 2026 -6.02M
March 31, 2026 -16.30M
December 31, 2025 -12.83M
September 30, 2025 -65.81M
June 30, 2025 -50.93M
March 31, 2025 -104.90M
December 31, 2024 -3.53M
September 30, 2024 -172.13M
June 30, 2024 -0.864M
March 31, 2024 -160.97M
December 31, 2023 -125.60M
September 30, 2023 -13.71M
Date Value
June 30, 2023 -13.99M
March 31, 2023 -14.09M
December 31, 2022 -4.786M
September 30, 2022 -21.71M
June 30, 2022 -2.328M
March 31, 2022 -91.40M
December 31, 2021 -11.46M
September 30, 2021 -4.18M
June 30, 2021 -0.865M
March 31, 2021 -14.02M
December 31, 2020 -111.37M
September 30, 2020 992.12M

Cash From Financing Definition

Represents the net cash flow resulting from the company's financing activities. Financing activities represent movement in the company's debt and share capital and other activities.

Read full definition.

Cash from Financing (Quarterly) Range, Past 5 Years

View Cash from Financing (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Financing (Quarterly) Benchmarks

View Cash from Financing (Quarterly) Benchmarks
Start Trial
LataMed AI Corp. 0.055M
SCWorx Corp. 0.00
Health Catalyst, Inc. -0.45M
Claritev Corp. -61.64M
iSpecimen, Inc. 2.285M